SCHEMBL4875205

SCHEMBL4875205

O=C(O)c1cc2c(s1)c(C1CCCCC1)c(-c1ccc3nc(-c4ccccc4C(F)(F)F)ccc3c1)n2CC(=O)N1CCC(N2CCCC2)CC1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
IRAK4 Q9NWZ3 3/20 0.36
GAA P10253 2/20 0.36
POLB P06746 1/20 0.36
TSHR P16473 1/20 0.36
CBX7 O95931 2/20 0.35
CDYL2 Q8N8U2 2/20 0.35
CDYL Q9Y232 2/20 0.35
CDY1; CDY1B Q9Y6F8 1/20 0.35
TP53 P04637 1/20 0.34
SMO Q99835 2/20 0.34
CYP2C9 P11712 2/20 0.34
ALDH1A1 P00352 1/20 0.34
KMT2A Q03164 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
ACHE P22303 1/20 0.33
SCD5 Q86SK9 1/20 0.33
LMNA P02545 1/20 0.33
RBP4 P02753 1/20 0.33
MTOR P42345 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4875217 0.91 POLB (0.38) IRAK4GAAPOLBTSHRCBX7
SCHEMBL4874410 0.89 TRPV4 (0.38) IRAK4GAAPOLBTSHR
SCHEMBL4877285 0.88 MAPT (0.36) IRAK4GAAPOLBTSHRCBX7
SCHEMBL4877463 0.88 GAA (0.36) IRAK4GAAPOLBTSHRCBX7
SCHEMBL4870793 0.88 CBX7 (0.37) GAAPOLBTSHRCBX7CDYL2
SCHEMBL4876782 0.87 GAA (0.37) IRAK4GAAPOLBTSHRCBX7
SCHEMBL4878274 0.87 TP53 (0.38) IRAK4GAAPOLBTSHRCBX7
SCHEMBL4878071 0.87 TP53 (0.35) IRAK4GAAPOLBTSHRCBX7
SCHEMBL4876386 0.87 MAPT (0.35) GAAPOLBTSHRTP53ALDH1A1
SCHEMBL4867002 0.86 IRAK4 (0.35) IRAK4GAAPOLBTSHRCBX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080051384-A1 ANTIVIRAL AGENTS GENELABS TECHNOLOGIES, INC. 2008-02-28 US disclosed
US-20080051384-A1 ANTIVIRAL AGENTS GENELABS TECHNOLOGIES, INC. 2008-02-28 US disclosed
US-20080051384-A1 ANTIVIRAL AGENTS GENELABS TECHNOLOGIES, INC. 2008-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080051384-A1 ANTIVIRAL AGENTS EIF2AK2, MAVS, ZC3HAV1 IRAK4 1626/4885GAA 66/4885POLB 327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.